

REFERENCES

- Ataseven, B. *et al.* (2016) “The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?,” *Gynecologic Oncology*. Elsevier Inc., 142(2), pp. 243–247.
- Aziz, M. F. (2009) “Gynecological cancer in Indonesia,” *Journal of Gynecologic Oncology*, 20(1), pp. 8–10.
- Barba, C. *et al.* (2004) “Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies,” *Lancet*, 363(9403), pp. 157–163.
- Bast, R. C., Romero, I. and Mills, G. B. (2014) “Molecular Pathogenesis of Ovarian Cancer,” in *Elsevier*, pp. 531–548.
- Bastaminejad, S. *et al.* (2017) “Investigation of microRNA-21 expression levels in serum and stool as a potential non-invasive biomarker for diagnosis of colorectal cancer,” *Iranian Biomedical Journal*, 21(2), pp. 106–113.
- Bethesda (MD): U.S. National Library of Medicine National Center for Biotechnology Information (2004) *TNF (tumor necrosis factor) gene*. Available at: https://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&dopt=full_report&list_ids=7124.
- Bio-Rad Laboratories (2011) “C1000 Touch™ Thermal Cycler Instruction Manual,” pp. 1–46.
- Block, M. S. *et al.* (2015) “Plasma immune analytes in patients with epithelial ovarian cancer,” *Cytokine*, 73(1), pp. 108–113.
- Boots, C. and Jungheim, E. (2015) “Inflammation and Human Ovarian Follicular Dynamics,” *Seminars in Reproductive Medicine*, 33(04), pp. 270–275.
- Bray, F. *et al.* (2018) “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *CA: A Cancer Journal for Clinicians*, 68(6), pp. 394–424.
- Brett M., R. *et al.* (2017) “Epidemiology of ovarian cancer: a review,” *Cancer Biology & Medicine*, 14(1), pp. 9–32. doi: 10.20892/j.issn.2095-3941.2016.0084.
- Clark, D. P., Pazdernik, N. J. and McGehee, M. R. (2019) “Nucleic Acids and Proteins,” in *Molecular Biology*. Elsevier, pp. 63–94.
- Dixon, S. C. *et al.* (2016) “Adult body mass index and risk of ovarian cancer by

- subtype: A Mendelian randomization study,” *International Journal of Epidemiology*, 45(3), pp. 884–895.
- Ehdaivand, S. (2017) *WHO classification of ovarian neoplasms*, *PathologyOutlines.com website*. Available at: <http://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html>.
- Gilks, B. (2018) “Ovary,” in *Rosai and Ackerman’s Surgical Pathology*. 11th ed. Elsevier Inc., pp. 1367–1431.
- Ham, B. *et al.* (2016) “The diverse roles of the TNF axis in cancer progression and metastasis.,” *Trends in cancer research*, 11(1), pp. 1–27.
- Intergrated DNA Technologies Inc. (2019) *Product Information*. Available at: idtdna.com.
- Koshiyama, M., Matsumura, N. and Konishi, I. (2014) “Recent Concepts of Ovarian Carcinogenesis: Type I and Type II,” *BioMed Research International*, 2014, pp. 1–11.
- Kurman, R. J. *et al.* (eds.) (2014) *WHO classification of tumours of the ovary*. 4th ed, *WHO classification of tumours of female reproductive organs*. 4th ed. International Agency for Research on Cancer.
- Kurman, R. J. and Shih, I. M. (2011) “Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - Shifting the paradigm,” *Human Pathology*. Elsevier Inc., 42(7), pp. 918–931.
- Leitzmann, M. F. *et al.* (2009) “Body mass index and risk of ovarian cancer,” *Cancer*, 115(4), pp. 812–822.
- Lekchnov, E. A. *et al.* (2016) “Protocol for miRNA isolation from biofluids,” *Analytical Biochemistry*, 499, pp. 78–84.
- Livak, K. J. and Schmittgen, T. D. (2001) “Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the $2^{-\Delta\Delta CT}$ Method,” *Methods*, 25(4), pp. 402–408.
- Macciò, A. and Madeddu, C. (2012) “Inflammation and ovarian cancer,” *Cytokine*, 58(2), pp. 133–147.
- Mahdi, B. M. (2011) “Role of some cytokines on reproduction,” *Middle East Fertility Society Journal*. Middle East Fertility Society, 16(3), pp. 220–223.
- Michaud, M. *et al.* (2013) “Proinflammatory Cytokines, Aging, and Age-Related Diseases,” *Journal of the American Medical Directors Association*, 14(12), pp. 877–882.

- Ministry of Health Indonesia (2015) “Pusat data dan informasi kementerian kesehatan Republik Indonesia, InfoDatin ‘STOP KANKER,’” *Ministry of Health Indonesia*, pp. 1–6.
- Mózes, T. *et al.* (2011) “Deviations in Circulating TNF α Levels and TNF α Production by Mononuclear Cells in Healthy Human Populations,” *Mediators of Inflammation*, 2011, pp. 1–8.
- Obeed, O. A. Al (2014) “Increased expression of tumor necrosis factor- α is associated with advanced colorectal cancer stages,” *World Journal of Gastroenterology*, 20(48), pp. 18390–18396.
- Olaitan, A. and Doufekas, K. (2014) “Clinical epidemiology of epithelial ovarian cancer in the UK,” *International Journal of Women’s Health*, 6, pp. 537–545.
- Piura, B. *et al.* (2014) “Distinct expression and localization of TNF system in ovarian carcinoma tissues: Possible involvement of TNF- α in morphological changes of ovarian cancerous cells,” *Anticancer Research*, 34(2), pp. 745–752.
- Popko, K. *et al.* (2010) “Proinflammatory cytokines Il-6 and TNF- α and the development of inflammation in obese subjects.,” *European journal of medical research*, 15 Suppl 2, pp. 120–122.
- Reid, F. (2018) *The World Ovarian Cancer Coalition Atlas: Global Trends in Incidence, Mortality and Survival*. World Ovarian Cancer Coalition.
- Rzymiski, P. *et al.* (2014) “The interaction between menstrual cycle, Tumour Necrosis Factor alpha receptors and sex hormones in healthy non-obese women – results from an observational study,” *Annals of Agricultural and Environmental Medicine*, 21(3), pp. 571–575.
- Savant, S., Sriramkumar, S. and O’Hagan, H. (2018) “The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer,” *Cancers*, 10(8), p. 251.
- Sciscione, A. (2019) *Ovarian Cancer, Ferri’s Clinical Advisor 2019: 5 Books in 1*. Elsevier.
- Shebl, F. M. *et al.* (2010) “Comparison of mRNA and Protein Measures of Cytokines following Vaccination with Human Papillomavirus-16 L1 Virus-like Particles,” *Cancer Epidemiology Biomarkers & Prevention*, 19(4), pp. 978–981.
- Sirotkin, A. V. (2011) “Cytokines: Signalling molecules controlling ovarian functions,” *International Journal of Biochemistry and Cell Biology*, 43(6), pp. 857–861.

- Staples, J. N. and Duska, L. R. (2019) "Cancer Screening and Prevention Highlights in Gynecologic Cancer," *Obstetrics and Gynecology Clinics of North America*. Elsevier Inc, 46(1), pp. 19–36.
- Still, S. (2016) "Tracking a Silent Killer: Ovarian Cancer," pp. 36–41.
- Szlosarek, P. W. *et al.* (2017) "Expression and regulation of tumor necrosis factor A in normal and malignant ovarian epithelium," *Molecular Cancer Therapy*, 5(1), pp. 382–390. doi: 10.1158/1535-7163.MCT-05-0303.
- Takeyama, H. *et al.* (1991) "Tumor Necrosis Factor Expression by Human Ovarian Carcinoma in Vivo," *Cancer Research*, 51(16), pp. 4476–4480.
- Terranova, P. F. (1997) "Potential roles of tumor necrosis factor- α in follicular development, ovulation, and the life span of the corpus luteum," *Domestic Animal Endocrinology*, 14(1), pp. 1–15.
- Torre, L. A. *et al.* (2018) "Ovarian cancer statistics, 2018," *CA: A Cancer Journal for Clinicians*, 68(4), pp. 284–296.
- Trabert, B. *et al.* (2014) "Gynecologic Oncology Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate , Lung , Colorectal and Ovarian Cancer (PLCO) Screening Trial," *Gynecologic Oncology*. Elsevier B.V., 135(2), pp. 297–304.
- Wang, X. and Lin, Y. (2008) "Tumor necrosis factor and cancer, buddies or foes?," *Acta Pharmacologica Sinica*, 29(11), pp. 1275–1288.
- Webb, P. M. and Jordan, S. J. (2017) "Epidemiology of epithelial ovarian cancer," *Best Practice and Research: Clinical Obstetrics and Gynaecology*. Elsevier Ltd, 41, pp. 3–14. doi: 10.1016/j.bpobgyn.2016.08.006.
- World Health Organization (2014) "Cancer Country Profile: Indonesia," *Cancer Country Profiles*, pp. 22–23. doi: 10.6%.
- World Health Organization (2017) *Cancer Tomorrow, Global Cancer Observatory*. Available at: <https://gco.iarc.fr/tomorrow/>.
- Zeng, F. *et al.* (2016) "Inflammatory markers of CRP, IL6, TNF α , and Soluble TNFR2 and the risk of ovarian cancer: A meta-analysis of prospective studies," *Cancer Epidemiology Biomarkers and Prevention*, 25(8), pp. 1231–1239.